Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 FDA approves tofacitinib for rheumatoid arthritis.

× No keyword cloud information.

25 in total

1. Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia.

Authors: B Bilori; S Thota; M J Clemente; B Patel; A Jerez; M Afable Ii; J P Maciejewski
Journal: Leukemia Date: 2015-10-09 Impact factor: 11.528

2. Development of a high-throughput crystal structure-determination platform for JAK1 using a novel metal-chelator soaking system.

Authors: Nicole L Caspers; Seungil Han; Francis Rajamohan; Lise R Hoth; Kieran F Geoghegan; Timothy A Subashi; Michael L Vazquez; Neelu Kaila; Ciarán N Cronin; Eric Johnson; Ravi G Kurumbail
Journal: Acta Crystallogr F Struct Biol Commun Date: 2016-10-27 Impact factor: 1.056

3. Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.

Authors: Young Ho Lee; Sang-Cheol Bae; Gwan Gyu Song
Journal: Rheumatol Int Date: 2015-05-21 Impact factor: 2.631

4. Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.

Authors: S-C Bae; Y H Lee
Journal: Z Rheumatol Date: 2019-08 Impact factor: 1.372

Review 5. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

Authors: Daniella M Schwartz; Yuka Kanno; Alejandro Villarino; Michael Ward; Massimo Gadina; John J O'Shea
Journal: Nat Rev Drug Discov Date: 2017-11-06 Impact factor: 84.694

6. The beneficial effect of baricitinib on ultrasound-detected synovial inflammation and bone damage in rheumatoid arthritis: Preliminarily data from single center-based observational study for 24 weeks.

Authors: Seong-Kyu Kim; Ui Hong Jung; Ji-Won Kim; Jung-Yoon Choe
Journal: Medicine (Baltimore) Date: 2021-07-30 Impact factor: 1.817

7. The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.

Authors: Matthew D Blunt; Stefan Koehrer; Rachel C Dobson; Marta Larrayoz; Sarah Wilmore; Alice Hayman; Jack Parnell; Lindsay D Smith; Andrew Davies; Peter W M Johnson; Pamela B Conley; Anjali Pandey; Jonathan C Strefford; Freda K Stevenson; Graham Packham; Francesco Forconi; Greg P Coffey; Jan A Burger; Andrew J Steele
Journal: Clin Cancer Res Date: 2016-10-03 Impact factor: 12.531

8. Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials.

Authors: Gwan Gyu Song; Sang-Cheol Bae; Young Ho Lee
Journal: Korean J Intern Med Date: 2014-08-28 Impact factor: 2.884

9. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.

Authors: Sarah C Davies; Isra M Hussein; Tran M Nguyen; Claire E Parker; Reena Khanna; Vipul Jairath
Journal: Cochrane Database Syst Rev Date: 2020-01-27

10. An Immuno-Cardiac Model for Macrophage-Mediated Inflammation in COVID-19 Hearts.

Authors: Liuliu Yang; Yuling Han; Fabrice Jaffré; Benjamin E Nilsson-Payant; Yaron Bram; Pengfei Wang; Jiajun Zhu; Tuo Zhang; David Redmond; Sean Houghton; Skyler Uhl; Alain Borczuk; Yaoxing Huang; Chanel Richardson; Vasuretha Chandar; Joshua A Acklin; Jean K Lim; Zhengming Chen; Jenny Xiang; David D Ho; Benjamin R tenOever; Robert E Schwartz; Todd Evans; Shuibing Chen
Journal: Circ Res Date: 2021-04-15 Impact factor: 23.213